Clinical course of patients with aspirin-exacerbated respiratory disease: can we predict the prognosis?

Abstract

AIM: This study aimed to identify prognostic factors of aspirin-exacerbated

respiratory disease by comparing clinical and genetic data with the clinical

course. PATIENTS & METHODS: Patients were classified into two groups according to

their response to inhalation rechallenge with lysine-aspirin after at least 1

year of regular treatment with antiasthmatic medications. RESULTS: Forty eight

patients (39.3%, group I) had negative responses, whereas 74 patients (60.7%,

group II) had positive responses (n = 23) or were not rechallenged owing to

persistent symptoms (n = 51). FEV(1) at diagnosis and follow-up were

significantly lower in group II than in group I. The CCR3 polymorphism at -520T/G

differed significantly between the two groups, whereas no difference was found in

other SNPs. CONCLUSION: Baseline FEV(1) and lower lung function after treatment

were clinical factors indicating a poor prognosis of aspirin-exacerbated

respiratory disease. The G allele of CCR3 -520T>G was associated with persistent

bronchial hypersensitivity to aspirin.